Prevalence and Impact of Manic Traits in Depressed Patients Initiating Interferon Therapy for Chronic Hepatitis C Infection

Journal of Clinical Gastroenterology

Volumn 44, Issue 7, 2010, Pages e148-e153

  Lim, Carmen ^a   Olson, Jeff ^a   Zaman, Atif ^b   Phelps, Jim ^b   Ingram, Kenneth D ^c  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b Division of Gastroenterology   (United States)

^c Co psychcom and Psych Educationorg ^*  (United States)

Author keywords

Bipolar disorder; Chronic hepatitis C; Depression; Interferon therapy

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; ANTIDEPRESSANT AGENT; RIBAVIRIN;

BIPOLAR DISORDER; CHEMICALLY INDUCED; COMPLICATION; FEMALE; HEPATITIS C, CHRONIC; HUMAN; MAJOR DEPRESSION; MALE; MIDDLE AGED; PREVALENCE; QUESTIONNAIRE; RETROSPECTIVE STUDY; ADULT; ARTICLE; CONTROLLED STUDY; DEPRESSION; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; GASTROINTESTINAL HEMORRHAGE; HEALTH SURVEY; HEPATIC ENCEPHALOPATHY; HEPATITIS C; INFECTION; LEUKOPENIA; MAJOR CLINICAL STUDY; MANIA; PRIORITY JOURNAL; PSYCHOSIS; SEIZURE; STRUCTURED QUESTIONNAIRE; SUICIDAL IDEATION;

ANTIVIRAL AGENTS; BIPOLAR DISORDER; DEPRESSIVE DISORDER, MAJOR; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; PREVALENCE; QUESTIONNAIRES; RETROSPECTIVE STUDIES;

EID: 77955171502     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0b013e3181dc24f8     Document Type: Article

References (52)

1. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med. 1999;341:556-562.
2. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med. 2001;345:41-52.
3. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975-982.
4. Ferenci P, Fried MW, Shiffman ML, et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40°KD)/ribavirin. Journal of Hepatology. 2005;43:425-433.
5. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology. 2002;36:s237-s244.
6. Russo MW, Fried MW. Side effects of therapy for chronic hepatitis C. Gastroenterology. 2003;124:1711-1719.
7. Raison CL, Borisov AS, Broadwell SD, et al. Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction. J Clin Psychiatry. 2005;66:41-48.
8. El-Serag HB, Kunik M, Richardson P, et al. Psychiatric disorders among veterans with hepatitis C infection. Gastroenterology. 2002;123:476-482.
9. Dieperink E, Willenbring ML, et al. A prospective study of neuropsychiatric symptoms associated with interferon-alpha 2b and ribavirin therapy for patients with chronic hepatitis C. Psychosomatics. 2003;44:104-112.
10. Miyaoka H, Kamijima K, et al. Depression from interferon therapy in patients with hepatitis C. Am J Psychiatry. 1999;156:1120.
11. Schaefer M, Gut O, et al. Interferon alpha and psychiatric syndromes: a review. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26:731-746.
12. Musselman DL, Bumnick JF et al. Paroxetine for the prevention of depression induced by high-dose interferon alpha. NEJM. 2001;344:961-966.
13. Hauser P, Aurora H, et al. A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Mol Psychiatry. 2002;7:942-947.
14. Goodwin FK, Jamison KR. Manic Depressive Illness: Bipolar Disorders and Recurrent Depression. 2nd edition. New York: Oxford University Press; 2007:765.
15. Altshulcer LL, Ackerman L, et al. Antidepressant-induced mania and cycle acceleration: a controversy revisited. Am J Psychiatry. 1995;152:1130-1138.
16. Shi L, McCombs JS, et al. The impact of unrecognized bipolar disorders for patients treated with for depression with antidepressants in the fee-for-services California Medicaid program. J Affect Disord. 2004;82:373-383.
17. El-Mallakh ES, Karippot A, Ghaemi NS. Antidepressants in bipolar depression. In: El-Mallakh ES, Ghaemi NS, eds. Bipolar Depression: A Comprehensive Guide. Arlington, Virginia: Amercian Psychiatric Publishing; 2006:167-183.
18. American Psychiatric Association. Practice Guideline for the treatment of patients with bipolar disorder. Am J Psychiatry. 2002;159:1-50.
19. Judd LL, Akiskal HS, Schettler PJ, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry. 2002;59:530-537.
20. Judd LL, Akiskal HS, Schettler PJ, et al. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry. 2003;60:261-269.
21. Judd LL, Asiskal HS. The prevalence and disability of bipolar spectrum disorders in the US population: re-analysis of the ECA database taking into account the subthreshold cases. J Affect Disord. 2003;73:123-131.
22. Ghaemi SN. Lack of insight in bipolar disorder: the acute manic episode. J Nerv Ment Disord. 1995;183:464-467.
23. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders DSM-IV-TR Fourth Edition. Washington DC: American Psychiatric Association; 2000:345-428.
24. Phelps JR, Ghaemi SN. Improving the diagnosis of bipolar disorder: predictive value of screening tests. J Affect Disord. 2006;92:141-148.
25. Bialek SR, Terrault NA. The changing epidemiology and natural history of hepatitis C virus infection. Clin Liver Dis. 2006;10:697-715.
26. Spitzer RL, Kroenke K, Williams JB. Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study??Primary Care Evaluation of Mental Disorders??Patient Health Questionnaire. JAMA. 1999;282:1737-1744.
27. Williams LS, Brizendine EJ, Plue L, et al. Performance of the PHQ-9 as a screening tool for depression after stroke. Stroke. 2005;36:635-638.
28. First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSM-4 Axis one disorders. New York: Biometric Research Unit, NY Psychiatric Institute; 1997:35.
29. Kroenke K, Spitzer RL, Williams JB. The Patient Health Questionnaire-2: validity of a two-item depression screener. Med Care. 2003;41:1284-1292.
30. Corson K, Gerrity MS, Dobscha SK. Screening for depression and suicidality in a VA primary care setting: 2 items are better than 1 item. Am J Manag Care. 2004;10:839-845.
31. Lowe B, Kroenke K, Grafe K. Detecting and monitoring depression with a two-item questionnaire (PHQ-2). J Psychosom Res. 2005;58:163-171.
32. Hirschfeld RM, Williams JB, Spitzer RL, et al. Development and validation of a screening instrument for bipolar spectrum disorder: the Mood Disorder Questionnaire. Am J Psychiatry. 2000;157:1873-1875.
33. Isometsa E, Suominen K, Mantere O, et al. The mood disorder questionnaire improves recognition of bipolar disorder in psychiatric care. BMC Psychiatry. 2003;3:8.
34. Benazzi F. Improving the Mood Disorder Questionnaire to detect bipolar II disorder. Can J Psychiatry. 2003;48:770-771.
35. Miller CJ, Klugman J, Berv DA, et al. Sensitivity and specificity of the Mood Disorder Questionnaire for detecting bipolar disorder. J Affect Disord. 2004;81:167-171.
36. Ghaemi SN. The Concepts of Psychiatry. Baltimore: Johns Hopkins Press; 2003:185-208.
37. Ghaemi SN, Miller CJ, Berv DA, et al. Sensitivity and specificity of a new bipolar spectrum diagnostic scale. J Affect Disord. 2005;84:273-277.
38. Olfson M, Das AK, Gameroff MJ, et al. Bipolar depression in a low-income primary care clinic. Am J Psychiatry. 2005;162:2146-2151.
39. Citrome L, Goldberg JF. The many faces of bipolar disorder. How to tell them apart. Postgrad Med. 2005;117:15-16, 19-23.
40. Kaye NS. Is your depressed patient bipolar?. J Am Board Fam Pract. 2005;18:271-281.
41. Kraus MR, Schafer A, Faller H, et al. Psychiatric symptoms in patients with chronic hepatitis C receiving interferon alfa-2b therapy. J Clin Psychiatry. 2003;64:708-714.
42. Constant A, Castera L, Dantzer R, et al. Mood alterations during interferon-alfa therapy in patients with chronic hepatitis C: evidence for an overlap between manic/hypomanic and depressive symptoms. J Clin Psychiatry. 2005;66:1050-1057.
43. Hirschfeld RM, Lewis L, Vornik LA. Perceptions and impact of bipolar disorder: how far have we really come? Results of the national depressive and manic-depressive association 2000 survey of individuals with bipolar disorder. J Clin Psychiatry. 2003;64:161-174.
44. Ghaemi SN, Sachs GS, Chiou AM, et al. Is bipolar disorder still underdiagnosed? Are antidepressants overutilized?. J Affect Disord. 1999;52:135-144.
45. Stoll AL, Tohen M, Baldessarini RJ, et al. Shifts in diagnostic frequencies of schizophrenia and major affective disorders at six North American psychiatric hospitals, 1972-1988. Am J Psychiatry. 1993;150:1668-1673.
46. Goldberg JF, Truman CJ. Antidepressant-induced mania: an overview of current controversies. Bipolar Disord. 2003;5:407-420.
47. Ghaemi SN. Hippocrates and Prozac: the controversy about antidepressants in bipolar disorder. Prim Psychiatry. 2006;13:51-58.
48. Sachs GS, Nierenberg AA, Calabrese JR, et al. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med. 2007;356:1711-1722.
49. Suppes T, Dennehy EB, Hirschfeld RM, et al. The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder. J Clin Psychiatry. 2005;66:870-886.
50. Yatham LN, Kennedy SH, O'Donovan C, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007. Bipolar Disord. 2006;8:721-739.
51. Amsterdam JD, Shults J. Fluoxetine monotherapy of bipolar type II and bipolar NOS major depression: a double-blind, placebo-substitution, continuation study. Int Clin Psychopharmacol. 2005;20:257-264.
52. Parker G, Tully L, Olley A, et al. SSRIs as mood stabilizers for Bipolar II Disorder? A proof of concept study. J Affect Disord. 2006;92:205-214.